serum response factor srf antibodies Search Results


93
Proteintech srf proteintech 16821 1 ap
Srf Proteintech 16821 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serum+response+factor+srf+antibodies/pmc05296651__ncomms14053___s1-107-37-38?v=Proteintech
Average 93 stars, based on 1 article reviews
srf proteintech 16821 1 ap - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
Novus Biologicals srf antibody
Srf Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serum+response+factor+srf+antibodies/pmc07760758-124-0-2?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
srf antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

86
Proteintech serum response factor srf
AGGF 1 regulates expression of phenotypic switching markers of vascular smooth muscle cells ( VSMC s). A, The platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) decreases the expression levels <t>of</t> <t>α‐</t> SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) at the protein level. PDGF ‐ BB does not affect the expression level of AGGF 1. B, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the protein level. C, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the mRNA level. NC indicates negative control. D, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in mouse VSMC line MOVAS ‐1 VSMC s. E, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in primary VSMC s isolated from mouse aortas. F, The expression levels of α‐ SMA , SM 22, and MYH 11 in MOVAS ‐1 VSMC s are significantly less than in primary mouse aortic VSMC s. G, Knockdown of <t>SRF</t> encoding the serum response factor by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the protein level. H, Knockdown of SRF by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the mRNA level. * P <0.05 (n=3/group). NS indicates not significant.
Serum Response Factor Srf, supplied by Proteintech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serum+response+factor+srf+antibodies/pmc05669188-31-18-31?v=Proteintech
Average 86 stars, based on 1 article reviews
serum response factor srf - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
Bio-Techne corporation serum response factor srf antibody
AGGF 1 regulates expression of phenotypic switching markers of vascular smooth muscle cells ( VSMC s). A, The platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) decreases the expression levels <t>of</t> <t>α‐</t> SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) at the protein level. PDGF ‐ BB does not affect the expression level of AGGF 1. B, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the protein level. C, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the mRNA level. NC indicates negative control. D, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in mouse VSMC line MOVAS ‐1 VSMC s. E, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in primary VSMC s isolated from mouse aortas. F, The expression levels of α‐ SMA , SM 22, and MYH 11 in MOVAS ‐1 VSMC s are significantly less than in primary mouse aortic VSMC s. G, Knockdown of <t>SRF</t> encoding the serum response factor by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the protein level. H, Knockdown of SRF by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the mRNA level. * P <0.05 (n=3/group). NS indicates not significant.
Serum Response Factor Srf Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/serum+response+factor+srf+antibodies/bio-techne+corporation___nbp1-87814?v=Bio-Techne+corporation
Average 90 stars, based on 1 article reviews
serum response factor srf antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

N/A
Serum Response Factor SRF rabbit polyclonal antibody Aff Purified
  Buy from Supplier

N/A
Serum Response Factor Antibody is a Rabbit Polyclonal against Serum Response Factor
  Buy from Supplier

N/A
The Serum Response Factor SRF Antibody from Novus is a Serum Response Factor SRF antibody to Serum Response Factor SRF. This antibody reacts with Human. The Serum Response Factor SRF antibody has been validated for
  Buy from Supplier

N/A
The Serum Response Factor SRF Antibody (PCRP-SRF-1F1) [DyLight 350] from Novus is a Serum Response Factor SRF antibody to Serum Response Factor SRF. This antibody reacts with Human. The Serum Response Factor SRF antibody has
  Buy from Supplier

N/A
The Serum Response Factor SRF Antibody (PCRP-SRF-1F1) [mFluor Violet 500 SE] from Novus is a Serum Response Factor SRF antibody to Serum Response Factor SRF. This antibody reacts with Human. The Serum Response Factor SRF
  Buy from Supplier

N/A
The Serum Response Factor SRF Antibody [Alexa Fluor® 488] from Novus is a Serum Response Factor SRF antibody to Serum Response Factor SRF. This antibody reacts with Human. The Serum Response Factor SRF antibody has
  Buy from Supplier

N/A
The Serum Response Factor SRF Antibody [DyLight 350] from Novus is a Serum Response Factor SRF antibody to Serum Response Factor SRF. This antibody reacts with Human. The Serum Response Factor SRF antibody has been
  Buy from Supplier

Image Search Results


AGGF 1 regulates expression of phenotypic switching markers of vascular smooth muscle cells ( VSMC s). A, The platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) decreases the expression levels of α‐ SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) at the protein level. PDGF ‐ BB does not affect the expression level of AGGF 1. B, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the protein level. C, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the mRNA level. NC indicates negative control. D, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in mouse VSMC line MOVAS ‐1 VSMC s. E, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in primary VSMC s isolated from mouse aortas. F, The expression levels of α‐ SMA , SM 22, and MYH 11 in MOVAS ‐1 VSMC s are significantly less than in primary mouse aortic VSMC s. G, Knockdown of SRF encoding the serum response factor by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the protein level. H, Knockdown of SRF by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the mRNA level. * P <0.05 (n=3/group). NS indicates not significant.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Targeting AGGF 1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury

doi: 10.1161/JAHA.117.005889

Figure Lengend Snippet: AGGF 1 regulates expression of phenotypic switching markers of vascular smooth muscle cells ( VSMC s). A, The platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) decreases the expression levels of α‐ SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) at the protein level. PDGF ‐ BB does not affect the expression level of AGGF 1. B, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the protein level. C, AGGF 1 blocks PDGF ‐induced downregulation of contractile markers at the mRNA level. NC indicates negative control. D, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in mouse VSMC line MOVAS ‐1 VSMC s. E, AGGF 1 increases the expression levels of α‐ SMA , SM 22, and MYH 11 in primary VSMC s isolated from mouse aortas. F, The expression levels of α‐ SMA , SM 22, and MYH 11 in MOVAS ‐1 VSMC s are significantly less than in primary mouse aortic VSMC s. G, Knockdown of SRF encoding the serum response factor by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the protein level. H, Knockdown of SRF by si RNA (si SRF ) abolishes the effect of AGGF 1 on PDGF at the mRNA level. * P <0.05 (n=3/group). NS indicates not significant.

Article Snippet: The 6xHis‐tagged AGGF1 protein was purified as described by us previously., , Antibodies against AGGF1, SM22, α‐SMA, MYH11, serum response factor (SRF), myocardin, and Enhanced Green Fluorescent Protein (EGFP) were from Proteintech.

Techniques: Expressing, Derivative Assay, Negative Control, Isolation, Knockdown

AGGF 1 regulates transcriptional activation of vascular smooth muscle cells ( VSMC s) phenotypic switching markers. A, Luciferase assays showing that AGGF 1 increases transcriptional activation of VSMC s contractile marker genes encoding α‐ SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) in the presence of SRF (serum response factor) ( SRF vs SRF +rh AGGF 1). NC indicates negative control. B, Luciferase assays showing that the platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) represses SRF ‐induced transcriptional activation of VSMC s contractile marker genes encoding α‐ SMA , SM 22, and MYH 11, but the effects are abolished by AGGF 1 protein. C, Chromatin immunoprecipitation assays to detect protein– DNA interaction between SRF and the CA rG elements at the promoter/regulatory regions of VSMC s contractile marker genes. PDGF reduces the SRF binding to CA rG elements, but the effects are abolished by AGGF 1 protein. D, Co‐immunoprecipitation assays showing that the AGGF 1 protein increases the interaction between SRF and myocardin in MOVAS ‐1 VSMC s with overexpression of both myocardin and SRF . An anti‐myocardin antibody was used for immunoprecipitation, and an anti‐ SRF antibody was used for immunoblotting. E, Co‐immunoprecipitation assays showing that PDGF reduced the interaction between SRF and myocardin, but the effect was reversed by AGGF 1. * P <0.05 and ** P <0.01 (n=3/group).

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Targeting AGGF 1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury

doi: 10.1161/JAHA.117.005889

Figure Lengend Snippet: AGGF 1 regulates transcriptional activation of vascular smooth muscle cells ( VSMC s) phenotypic switching markers. A, Luciferase assays showing that AGGF 1 increases transcriptional activation of VSMC s contractile marker genes encoding α‐ SMA (α smooth muscle actin), SM 22 (smooth muscle protein 22‐α or transgelin), and MYH 11 (myosin heavy polypeptide 11, smooth muscle) in the presence of SRF (serum response factor) ( SRF vs SRF +rh AGGF 1). NC indicates negative control. B, Luciferase assays showing that the platelet‐derived growth factor subunit B homodimer ( PDGF ‐ BB ) represses SRF ‐induced transcriptional activation of VSMC s contractile marker genes encoding α‐ SMA , SM 22, and MYH 11, but the effects are abolished by AGGF 1 protein. C, Chromatin immunoprecipitation assays to detect protein– DNA interaction between SRF and the CA rG elements at the promoter/regulatory regions of VSMC s contractile marker genes. PDGF reduces the SRF binding to CA rG elements, but the effects are abolished by AGGF 1 protein. D, Co‐immunoprecipitation assays showing that the AGGF 1 protein increases the interaction between SRF and myocardin in MOVAS ‐1 VSMC s with overexpression of both myocardin and SRF . An anti‐myocardin antibody was used for immunoprecipitation, and an anti‐ SRF antibody was used for immunoblotting. E, Co‐immunoprecipitation assays showing that PDGF reduced the interaction between SRF and myocardin, but the effect was reversed by AGGF 1. * P <0.05 and ** P <0.01 (n=3/group).

Article Snippet: The 6xHis‐tagged AGGF1 protein was purified as described by us previously., , Antibodies against AGGF1, SM22, α‐SMA, MYH11, serum response factor (SRF), myocardin, and Enhanced Green Fluorescent Protein (EGFP) were from Proteintech.

Techniques: Activation Assay, Luciferase, Marker, Negative Control, Derivative Assay, Chromatin Immunoprecipitation, Binding Assay, Immunoprecipitation, Over Expression, Western Blot